Status:
UNKNOWN
Influence of Sarcopenia in Hepatocellular Carcinoma Patients
Lead Sponsor:
Sohag University
Conditions:
Sarcopenia
Eligibility:
All Genders
18+ years
Brief Summary
Liver cancer poses a major threat to the global cancer burden, and the number of deaths is estimated to be more than one million annually by 2030. Locoregional therapies such as transarterial chemoemb...
Eligibility Criteria
Inclusion
- Clinical diagnosis of hepatocellular carcinoma.
- Treatment-naive patients who underwent local ablation, TACE or sorafenib as a primary treatment .
Exclusion
- Use of other another HCC treatment modality e.g., resection.
- Use of combined treatments e.g., simultaneous use of embolic therapy with ablation.
- Patients with recurrent HCC.
- Patients with secondaries from extra-hepatic primary tumors.
- Incomplete data at the diagnosis, treatment or follow up time-points.
- Loss of patients follow up.
Key Trial Info
Start Date :
February 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06177496
Start Date
February 1 2024
End Date
December 1 2024
Last Update
December 20 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.